Dr. Abida on Future of Hormonal Therapy in Prostate Cancer

Wassim Abida, MD, PhD
Published: Wednesday, Feb 01, 2017



Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Targeting androgen receptors (AR) is a topic being explored, specifically the parts of AR that are not already being targeted. There are other targets worth attention beyond the C-terminal ligand binding domain, says Abida.

These targets include AR-V7, but new drugs need to be developed that target the protein within it. According to Abida, that is worth exploring even though it is not known whether it will yield a response.

Combination therapy is also an approach that is being looked at as the future of hormonal therapy in prostate cancer.
 


Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Targeting androgen receptors (AR) is a topic being explored, specifically the parts of AR that are not already being targeted. There are other targets worth attention beyond the C-terminal ligand binding domain, says Abida.

These targets include AR-V7, but new drugs need to be developed that target the protein within it. According to Abida, that is worth exploring even though it is not known whether it will yield a response.

Combination therapy is also an approach that is being looked at as the future of hormonal therapy in prostate cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x